| Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients N Gangat, O Karrar, M Iftikhar, K McCullough, IM Johnson, M Abdelmagid, ... American journal of hematology 99 (2), 193-202, 2024 | 17 | 2024 |
| Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases KK Reichard, A Tefferi, M Abdelmagid, A Orazi, C Alexandres, J Haack, ... Blood cancer journal 12 (11), 147, 2022 | 16 | 2022 |
| Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases A Singh, A Al‐Kali, KH Begna, MR Litzow, JT Larsen, T Sher, ... American journal of hematology 97 (5), 630-637, 2022 | 11 | 2022 |
| Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and … O Karrar, M Abdelmagid, M Rana, M Iftikhar, K McCullough, A Al-Kali, ... American journal of hematology 99 (2), E63-E66, 2024 | 8 | 2024 |
| ABO blood group type and risk of venous thrombosis in essential thrombocythemia OS Karrar, M Abdelmagid, AM Vannucchi, T Barbui, A Tefferi, N Gangat British journal of haematology 202, 699-703, 2023 | 5 | 2023 |
| CALR mutation burden in essential thrombocythemia and disease outcome P Guglielmelli, N Szuber, N Gangat, G Capecchi, C Maccari, M Harnois, ... Blood 143 (13), 1310-1314, 2024 | 4 | 2024 |
| Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival MG Abdelmagid, A Al-Kali, KH Begna, WJ Hogan, MR Litzow, F Fleti, ... Haematologica 108 (9), 2542, 2023 | 3 | 2023 |
| TP53 mutations and variant allele frequency in myelodysplastic syndromes with del (5q): A Mayo-Moffitt study of 156 informative cases F Fleti, O Chan, A Singh, MG Abdelmagid, A Al-Kali, MA Elliott, KH Begna, ... American journal of hematology 98 (4), E76-E79, 2023 | 3 | 2023 |
| Lenalidomide therapy for primary myelodysplastic syndromes with isolated del (5q): determinants of response and survival in a real-world setting A Singh, A Al-Kali, JM Foran, MA Elliott, K Begna, T Badar, N Khera, ... American journal of hematology 97 (10), E377-E379, 2022 | 3 | 2022 |
| Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases MG Abdelmagid, MR Litzow, KB McCullough, N Gangat, A Pardanani, ... Blood cancer journal 12 (7), 103, 2022 | 3 | 2022 |
| Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases A Tefferi, M Abdelmagid, A Al‐Kali, M Patnaik, WJ Hogan, K Begna, ... American journal of hematology 99 (1), 21-27, 2024 | 2 | 2024 |
| IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience N Gangat, H Ajufo, M Abdelmagid, O Karrar, K McCullough, T Badar, ... British journal of haematology 203 (3), e87-e92, 2023 | 2 | 2023 |
| Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial … MG Abdelmagid, A Al-Kali, MR Litzow, KH Begna, WJ Hogan, MS Patnaik, ... Blood cancer journal 13 (1), 122, 2023 | 2 | 2023 |
| Leukemic transformation of myeloproliferative neoplasms in the post-Ruxolitinib era: analysis of 103 consecutive cases diagnosed 2011-2021 M Abdelmagid, A Al-Kali, KH Begna, WJ Hogan, MR Litzow, ... Blood 140 (Supplement 1), 9735-9736, 2022 | 2 | 2022 |
| Calr variant allele frequency in essential thrombocythemia: molecular associations and impact on disease phenotype and outcome P Guglielmelli, N Szuber, N Gangat, G Capecchi, C Maccari, L Busque, ... Blood 142, 6328, 2023 | 1 | 2023 |
| Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia N Gangat, K McCullough, M Abdelmagid, O Karrar, M Powell, A Al-Kali, ... Haematologica 109 (1), 287, 2024 | | 2024 |
| ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival K McCullough, O Karrar, M Iftikhar, M Abdelmagid, A Al-Kali, H Alkhateeb, ... Blood 142, 5925, 2023 | | 2023 |
| Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency M Abdelmagid, KK Reichard, O Karrar, R He, P Greipp, R Ketterling, ... Blood 142, 4214, 2023 | | 2023 |
| Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk N Gangat, O Karrar, M Abdelmagid, M Iftikhar, KK Reichard, N Szuber, ... Blood 142, 1815, 2023 | | 2023 |
| ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis M Abdelmagid, J Palmer, JM Foran, A Al-Kali, O Karrar, KK Reichard, ... Blood 142, 3194, 2023 | | 2023 |
